DaVita Appoints New CFO, Joel Ackerman

TL;DR

DaVita names Joel Ackerman as new CFO, starting Aug 12 with $600K salary + bonuses.

AI Summary

On August 8, 2024, DaVita Inc. filed an 8-K report to disclose the appointment of a new Chief Financial Officer, Joel G. Ackerman, effective August 12, 2024. He will receive an annual base salary of $600,000 and is eligible for a discretionary annual bonus. Ackerman will also receive a sign-on bonus of $500,000 and equity awards valued at $3,000,000.

Why It Matters

The appointment of a new CFO is a significant leadership change that can impact investor confidence and the company's financial strategy.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of executive appointment and compensation, with no immediate financial distress or significant operational changes indicated.

Key Numbers

• $600,000 — Annual Base Salary (For new CFO Joel G. Ackerman)
• $500,000 — Sign-on Bonus (For new CFO Joel G. Ackerman)
• $3,000,000 — Equity Awards Value (For new CFO Joel G. Ackerman)

Key Players & Entities

• DaVita Inc. (company) — Registrant
• Joel G. Ackerman (person) — Newly appointed Chief Financial Officer
• $600,000 (dollar_amount) — Annual base salary for Joel G. Ackerman
• $500,000 (dollar_amount) — Sign-on bonus for Joel G. Ackerman
• $3,000,000 (dollar_amount) — Value of equity awards for Joel G. Ackerman
• August 12, 2024 (date) — Effective date for Joel G. Ackerman's appointment

FAQ

From the Filing

0001206774-24-000776.txt : 20240809 0001206774-24-000776.hdr.sgml : 20240809 20240808181719 ACCESSION NUMBER: 0001206774-24-000776 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240808 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240809 DATE AS OF CHANGE: 20240808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DAVITA INC. CENTRAL INDEX KEY: 0000927066 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 510354549 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14106 FILM NUMBER: 241189914 BUSINESS ADDRESS: STREET 1: 2000 16TH STREET CITY: DENVER STATE: CO ZIP: 80202 BUSINESS PHONE: 310-536-2668 MAIL ADDRESS: STREET 1: 2000 16TH STREET CITY: DENVER STATE: CO ZIP: 80202 FORMER COMPANY: FORMER CONFORMED NAME: DAVITA HEALTHCARE PARTNERS INC. DATE OF NAME CHANGE: 20121107 FORMER COMPANY: FORMER CONFORMED NAME: DAVITA INC DATE OF NAME CHANGE: 20001005 FORMER COMPANY: FORMER CONFORMED NAME: TOTAL RENAL CARE HOLDINGS INC DATE OF NAME CHANGE: 19950524 8-K 1 dva4364011-8k.htm CURRENT REPORT false 0000927066 0000927066 2024-08-08 2024-08-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024   DAVITA INC. (Exact name of registrant as specified in its charter)         Delaware 1-14106   51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2000 16 th Street Denver , CO 80202 (Address of principal executive offices including Zip Code) ( 720 ) 631-2100 (Registrant’s telephone number, including area code) Not applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 240.425) ☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class:   Trading symbol(s):   Name of each exchange on which registered: Common Stock, $0.001 par value   DVA   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐         Item 8.01. Other Events. On August 8, 2024, DaVita Inc. (the “Company”) issued a press release, made pursuant to Rule 135c promulgated under the Securities Act of 1933, as amended, announcing the pricing of its previously announced private offering (the “Notes Offering”) of $1.0 billion aggregate principal amount of the Company’s 6.875% Senior Notes due 2032 (the “2032 Notes”